| BUYER | Anupam Rasayan India Ltd (Surat; NSE: ANURAS), custom synthesis and specialty chemicals, acting with its subsidiary Mates Visa Consultancy Pvt Ltd |
|---|
| TARGET | Bliss GVS Pharma Ltd (BSE: 506197), Mumbai-listed formulations maker founded 1984, about 91% exports (secondary aggregator) |
| AGREEMENT | Share purchase agreement signed 23 May 2026 · promoter block of 5,09,84,595 shares (47.95%) completed 28 Sep 2026 at ₹299 |
| COMBINED HOLDING | About 50.07% with the buyer's partner, after a further 22.5 lakh shares bought on the market at ₹723.28 (₹162.74 Cr) |
| TOTAL COST | ₹1,750 Cr including ₹50 Cr of expenses (other reports: ₹1,360 Cr, ₹1,369.51 Cr at signing) |
| FUNDING | ₹300 Cr term loan plus about ₹1,450 Cr of non-voting instruments from investors led by Bain Capital, including Trust Group and Investec |
| OPEN OFFER | 26%, up to 2,77,26,848 shares at ₹299, up to ₹829.03 Cr |
| COMBINED GROUP | Pro forma revenue above ₹4,000 Cr and EBITDA about ₹834 Cr across Anupam, Tanfac, Jayhawk and Bliss GVS (company statement); Bliss GVS pro forma revenue ₹927 Cr |
| THE ACCESS POINT
Both companies are listed. Anupam Rasayan and Bliss GVS Pharma shares trade on NSE and BSE and can be bought in the market. |
|---|
Executive decision summary
| THE BOTTOM LINE | Anupam Rasayan, a custom-synthesis chemicals maker, took control of Bliss GVS Pharma, a formulations exporter, in a deal reported at about ₹1,750 crore. The agreement was signed on 23 May 2026 and the 47.95% promoter block was bought on 28 September 2026 at ₹299 a share. A further 22.5 lakh shares were bought on the market at ₹723.28, far above the ₹299 contract price, taking the combined holding to about 50.07%. The money came from a ₹300 crore term loan and about ₹1,450 crore of non-voting instruments from investors led by Bain Capital. Bliss GVS earned a reported ₹134.73 crore profit on about ₹1,000 crore of income in FY26 and has almost no debt. The record has conflicts: stake percentage, total cost and the buyer's FY26 and the target's revenue differ across outlets. |
|---|
| WHICH INVESTOR | The deal fits a pharma and chemicals watcher IF you follow Indian companies using outside capital to buy control of listed pharma units.
Wait IF you need a clean price, the legal form of the ₹1,450 crore instruments or Bliss GVS EBITDA: none was confirmed. |
| COMFORT FIT | Custom synthesis = making specialty chemicals to a customer's order, often for pharma or agriculture.
Formulations = finished medicines such as tablets, as against the raw chemicals that go into them.
Non-voting instruments = money put in for a return but with no vote, so the buyer keeps control.
Person acting in concert = a related party counted together with the buyer for stake and open-offer purposes. |
| THE RUPEIA NUMBER | ₹299 against ₹723.28. The contract price per share for the promoter block, against the price paid for 22.5 lakh shares on the market, which was 2.4 times as high. |
1 CLAIM REGISTER: EVIDENCE GRADING
| Claim | Source | Grade | Rupeia assessment |
|---|
| SPA signed 23 May 2026; promoter block 47.95% completed 28 Sep at ₹299 | Medical Dialogues; Indian Pharma Post; Whalesbook | C | Established |
| Total cost ₹1,750 Cr including ₹50 Cr expenses | Medical Dialogues; Indian Pharma Post | C | Reported total |
| Combined stake 50.07% (48.2% in Indian Pharma Post and Medical Dialogues headlines; 43.3% or up to 74.2% at signing) | Various | D | Conflict across outlets |
| Funding: ₹300 Cr loan plus about ₹1,450 Cr of non-voting instruments led by Bain Capital | Indian Pharma Post; Medical Dialogues | C | Legal form not published in sources read |
| Bliss GVS FY26 PAT ₹134.73 Cr; income ₹1,000.64 Cr | Whalesbook | C | Single detailed source; revenue ranges ₹809–1,015 Cr elsewhere |
| Seller names | Whalesbook (aggregator) | D | Not checked against a filing |
2 THE DEAL: STAKE, PRICE AND OPEN OFFER
| Item | Detail |
|---|
| Promoter block | 5,09,84,595 shares, 47.95%, at ₹299 (another report prints 5,09,86,264) |
| On-market top-up | 22,50,000 shares at ₹723.28, ₹162.74 Cr |
| Open offer | 26%, up to 2,77,26,848 shares at ₹299, up to ₹829.03 Cr; call option on 51,81,571 shares (4.90%) |
| Figure at signing in May | "Over ₹1,360 Cr" for up to 74.2% (Venture Intelligence); ₹1,369.51 Cr for 43.3% (Whalesbook) |
| Sellers (aggregator) | Promoters Shruti Vishal Rao, Vibha Gagan Sharma and Narsimha Shibroor Kamath; non-promoters Gautam Rasiklal Ashra, Arjun Gautam Ashra and Gulbarga Trading and Investment; sellers' counsel Kanga & Co |
| Promoter holding before | Reported at 35.01% in June 2026 (Multibagg) |
| Calculation (Rupeia) | Result |
|---|
| Cost of the promoter block | 5,09,84,595 × ₹299 ≈ ₹1,524 Cr |
| Top-up check | 22,50,000 × ₹723.28 = ₹162.7 Cr, matching ₹162.74 Cr |
| Sum with ₹50 Cr of expenses | ₹1,524 Cr + ₹163 Cr + ₹50 Cr ≈ ₹1,737 Cr, within 0.7% of the ₹1,750 Cr headline |
| Total shares in the company | 2,77,26,848 ÷ 26% ≈ 10.66 crore (the promoter block gives 10.63 crore) |
| Top-up share of the company | 22.5 lakh ÷ 10.65 crore ≈ 2.1%; 47.95% + 2.1% = 50.06%, matching 50.07% |
| Open offer maximum | 2,77,26,848 × ₹299 = ₹829.0 Cr |
| Top-up price against contract price | ₹723.28 ÷ ₹299 = 2.42x |
| RUPEIA READ
The headline cost makes sense only if the on-market purchase is counted: the promoter block at ₹299 plus the top-up and expenses lands within a rounding gap of ₹1,750 crore. The price gap, ₹299 on the contract against ₹723.28 on the market, is large and the sources do not explain it. If the shares were trading near ₹723, the ₹299 open offer sits far below the market, as in the Novartis India deal (Report 56), and few public holders would tender. |
|---|
3 FUNDING: WHO PAID FOR CONTROL
| Source of money | Amount | Detail |
|---|
| Term loan | ₹300 Cr | Lender not named in sources read |
| Non-voting instruments | About ₹1,450 Cr | Investors led by Bain Capital, with Trust Group and Investec; legal form and terms not published |
| Total | About ₹1,750 Cr | Matches the headline cost |
| Calculation (Rupeia) | Result |
|---|
| Outside instruments as share of total | ₹1,450 Cr ÷ ₹1,750 Cr = 83% |
| Term loan as share of total | ₹300 Cr ÷ ₹1,750 Cr = 17% |
| Anupam FY26 profit against the instruments | ₹222 Cr ÷ ₹1,450 Cr = 15% a year, before any return owed on the instruments |
| RUPEIA READ
More than four-fifths of the money came from outside investors in instruments that carry no vote. That keeps control with the Desai family but means the instruments will take a return from Anupam and Bliss GVS cash flows. Without the terms, the cost of that capital and any repayment schedule cannot be assessed. This is the largest disclosure gap in the deal. |
|---|
4 THE TARGET: BLISS GVS PHARMA
| Measure (FY26, to 31 Mar 2026) | Value | Source quality |
|---|
| Total income | ₹1,000.64 Cr, up 18.25% from ₹846.22 Cr | Whalesbook |
| Revenue elsewhere | ₹927 Cr (pro forma), ₹809.73 Cr and ₹1,015.45 Cr | Other outlets |
| Profit after tax | ₹134.73 Cr against ₹96.87 Cr (reported as up 49%) | Whalesbook |
| Net worth | ₹1,231.76 Cr | Whalesbook |
| Borrowings | ₹2.93 Cr | Whalesbook |
| EBITDA | Not confirmed; an aggregator lists ₹238 Cr; Q4 EBITDA ₹55.63 Cr (secondary) | Aggregators |
| Exports | About 91% of sales, Sub-Saharan Africa about 80% | Aggregator summary, not verified |
| Capacity use | About 30%, target 70–80%, no timeline | Medical Dialogues; Indian Pharma Post |
| Calculation (Rupeia) | Result |
|---|
| Profit growth check | ₹134.73 Cr ÷ ₹96.87 Cr − 1 = 39.1%, not the 49% reported |
| Revenue growth check | ₹1,000.64 Cr ÷ ₹846.22 Cr − 1 = 18.25%, as reported |
| Profit margin on total income | ₹134.73 Cr ÷ ₹1,000.64 Cr = 13.5% |
| Equity value of 100% at ₹299 | 10.66 crore × ₹299 ≈ ₹3,188 Cr |
| Price to earnings at ₹299 | ₹3,188 Cr ÷ ₹134.73 Cr ≈ 23.7x |
| Price to book at ₹299 | ₹3,188 Cr ÷ ₹1,231.76 Cr ≈ 2.6x |
| Equity value at ₹723.28 | 10.66 crore × ₹723.28 ≈ ₹7,710 Cr, about 57x FY26 profit |
| RUPEIA READ
The earlier research note estimated about 13 times earnings by dividing ₹1,750 crore by profit, but that mixes the cost of a half stake with the profit of the whole company. Valuing the whole company at the ₹299 contract price gives about 24 times earnings and 2.6 times book value, with almost no debt. At the ₹723 top-up price, the same arithmetic gives about 57 times earnings. The reported 49% profit growth does not match the two profit figures, which give 39%, so one of the numbers needs checking. |
|---|
5 THE BUYER: ANUPAM RASAYAN
| Measure | Value | Source quality |
|---|
| FY26 revenue | ₹2,383.6 Cr, up about 65% (MarketsMojo shows ₹2,365.46 Cr) | Whalesbook |
| FY26 EBITDA and PAT | ₹543 Cr (23%) and ₹222 Cr | Secondary sources |
| Q1 FY27 revenue | ₹654.98 Cr, up about 35%; EBITDA ₹162 Cr (24.8%) or ₹174.9 Cr (26.2%) | Indian Pharma Post |
| FY27 growth guidance | Over 30%, raised from 20–25% | Sahi |
| Pro forma combined | Revenue above ₹4,000 Cr: Anupam ₹1,676 Cr, Tanfac ₹711 Cr, Jayhawk ₹722 Cr, Bliss GVS ₹927 Cr; EBITDA about ₹834 Cr | Company statement via Medical Dialogues |
| Earlier deals | Tanfac Industries 24.96% (2022); Jayhawk Fine Chemicals (Kansas, US) 100%, enterprise value about US$134m, closed 27 Feb 2026 | Venture Intelligence; The Week |
| Calculation (Rupeia) | Result |
|---|
| Components of the ₹4,000 Cr claim | ₹1,676 + ₹711 + ₹722 + ₹927 = ₹4,036 Cr |
| Pro forma EBITDA margin | ₹834 Cr ÷ ₹4,036 Cr = 20.7%, below Anupam's own 23% |
| Bliss GVS share of the pro forma revenue | ₹927 Cr ÷ ₹4,036 Cr = 23% |
| Anupam FY26 EBITDA margin | ₹543 Cr ÷ ₹2,383.6 Cr = 22.8% |
Anand Desai is Managing Director of Anupam Rasayan and has been with the company since 1992. Mona Desai is Vice Chairman and Whole-Time Director. Ravi Desai became Chief Operating Officer on 14 August 2026. No chief executive is named in the sources read. A Tech Mahindra link suggested in the research brief was not found in any source.
| RUPEIA READ
Anupam has used outside capital three times in about three years: Tanfac, Jayhawk and now Bliss GVS. Its pro forma margin of 20.7% is below its standalone margin of 22.8%, which means the acquired businesses dilute margin until capacity use at Bliss GVS rises from about 30%. No timeline for that has been published. |
|---|
6 SECTOR CONTEXT: PHARMA M&A IN 2026
| Datapoint | Detail | Source |
|---|
| September 2026 healthcare M&A | ₹19 bn from three main deals; pharma 88.8% of value; healthtech 10% | Equirus via Indian Pharma Post, 6 Oct 2026 |
| Year to date | Pharma 91.4% of healthcare M&A value; calendar 2025 share 71% | Equirus |
| Other September deal | RPG Active Pharma buys Raghava Life Sciences' API and intermediates business for ₹135 Cr | Indian Pharma Post |
| Q3 2026 deal volume | 87 deals, US$4.3bn, a record number | Grant Thornton |
| Largest 2026 deal mentioned | Sun Pharma and Organon, US$11.8bn, announced April 2026 | Grant Thornton |
| RUPEIA READ
Pharma is taking an unusually large share of healthcare deal value in 2026, and buyers range from private equity (ChrysCapital, Creador) to chemical companies moving downstream into finished medicines. Anupam is an example of the second type: a supplier of ingredients buying a formulations company with its own markets. |
|---|
7 RISKS, SCENARIOS AND CHECKLIST
| Risk | Evidence | Severity | Kill condition |
|---|
| Disclosure on funding | ₹1,450 Cr of instruments, terms unpublished | HIGH | Return and repayment terms prove heavy |
| Price conflicts | ₹299 contract vs ₹723.28 top-up; stake 43–50% | MEDIUM | Filing shows higher effective cost |
| Margin dilution | Pro forma 20.7% against 22.8% | MEDIUM | Bliss GVS utilisation stays near 30% |
| Concentration | Exports about 91%, Sub-Saharan Africa about 80% (aggregator) | MEDIUM | African demand or payment shocks |
| Leverage | ₹300 Cr term loan plus instruments | MEDIUM | Cash flow below service needs |
| Evidence quality | Seller names and Bliss GVS EBITDA from aggregators | MEDIUM | Filings differ |
| Scenario | What happens | Outcome |
|---|
| Bull | Utilisation rises to 70%; platform reaches ₹4,000 Cr revenue | Margins recover |
| Base | Slow ramp-up; instruments serviced from cash flow | Moderate return |
| Bear | Export shock and heavy instrument costs | Profit squeezed |
| Investor class | Fit | Why |
|---|
| Listed-market investor in Anupam | PARTIAL | Growth guidance over 30%, but funding terms unknown |
| Listed-market investor in Bliss GVS | WAIT | Open-offer outcome and price gap unclear |
| Short-term trader | LOW | Events: open-offer completion and instrument terms |
Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. Open items are the terms of the instruments, the open-offer result and Bliss GVS EBITDA.
8 KEY TERMS USED IN THIS REPORT
The terms below are used in this report. Each is explained in plain words.
| Term | Meaning |
|---|
| Person acting in concert (PAC) | A related party counted with the buyer for stake and open-offer rules. |
| Non-voting instrument | An investment that earns a return but carries no vote. |
| Custom synthesis | Making specialty chemicals to a customer's specification. |
| Formulations | Finished medicines such as tablets and syrups. |
| Open offer | A required offer to buy 26% from public shareholders after control changes. |
| Pro forma | Results shown as if the deal had been in place for the whole period. |
Frequently asked questions
What did Anupam Rasayan buy?
Control of Bliss GVS Pharma, through a promoter block of 47.95% bought at ₹299 a share, completed on 28 September 2026, plus a market purchase that took its combined holding to about 50.07%.
How much did it cost?
About ₹1,750 crore including ₹50 crore of expenses, according to Medical Dialogues and Indian Pharma Post. Earlier reports in May gave about ₹1,360 crore.
How was it funded?
A ₹300 crore term loan and about ₹1,450 crore of non-voting instruments from investors led by Bain Capital, with Trust Group and Investec.
What is the open offer?
26% of Bliss GVS, up to 2,77,26,848 shares at ₹299, worth up to ₹829 crore if fully accepted.
What does Bliss GVS earn?
FY26 total income of about ₹1,000 crore and profit after tax of ₹134.73 crore, with borrowings of ₹2.93 crore, per Whalesbook. Other outlets give different revenue.
What is the combined group's size?
The company says pro forma revenue is above ₹4,000 crore and EBITDA about ₹834 crore, including Tanfac and Jayhawk.
Source log
Indian Pharma Post: Anupam Rasayan completes ₹1,750 Cr acquisition of Bliss GVS Pharma
Medical Dialogues: Anupam acquires 48.2% in Bliss GVS Pharma for ₹1,750 Cr
Bar & Bench: Anupam controlling stake; Kanga & Co advises sellers
Venture Intelligence: Anupam to acquire Bliss GVS Pharma (₹1,360 Cr)
Whalesbook: Bliss GVS FY26 results
Whalesbook: Anupam to acquire 26% via ₹299 open offer
Whalesbook: Anupam FY26 revenue up 65%
Indian Pharma Post: Pharma dominates Indian healthcare M&A
The Week: Anupam Rasayan completes US$150m Jayhawk acquisition
Grant Thornton: Pharma and Healthcare Dealtracker Q3 2026
| DISCLAIMER
This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. |
|---|